Juhun Lee

Juhun Lee

Auto-generated profile, based on publicly available information

Juhun Lee

Department of Life Sciences, Pohang University of Science and Technology, Pohang 37673, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 February 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
BKByeong-Rak Keum
Byeong-Rak Keum
HKHong Jin Kim
Hong Jin Kim
JLJuhun Lee
Juhun Lee
MLMinji Lee
Minji Lee
SHSin-Hyoung Hong
Sin-Hyoung Hong
GKGun-Hwa Kim
Gun-Hwa Kim
Postmenopausal osteoporosis arises from imbalanced osteoclast and osteoblast activity, and mounting evidence suggests a role for the osteoimmune system in bone homeostasis. Bisphosphonate (BP) is an antiresorptive agent, but its treatment failure rate can be as high as 40%. Here, we performed single-cell RNA sequencing on peripheral immune cells from carefully selected postmenopausal women: non-osteoporotic, osteoporosis improved after BP treatment, and BP-failed cases. We found an increase in myeloid cells in patients with osteoporosis (specifically, T cell receptor+ macrophages). Furthermore, lymphoid lineage cells varied significantly, notably elevated natural killer cells (NKs) in the BP-failed group. Moreover, we provide fruitful lists of biomarkers within the immune cells that exhibit condition-dependent differences. The existence of osteoporotic- and BP-failure-specific cellular information flows was revealed by cell–cell interaction analysis. These findings deepen our insight of the osteoporosis pathology enhancing comprehension of the role of immune heterogeneity in postmenopausal osteoporosis and BP treatment failure.

2 February 2024 in Science Advances
Verified
Journal Article
Open access
JLJuhun Lee
Juhun Lee
DKDonghyo Kim
Donghyo Kim
JKJungHo Kong
JungHo Kong
DHDoyeon Ha
Doyeon Ha
IKInhae Kim
Inhae Kim
SKSanguk Kim
Sanguk Kim
Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment. However, only some patients respond to ICIs, and current biomarkers for ICI efficacy have limited performance. Here, we devised an interpretable machine learning (ML) model trained using patient-specific cell-cell communication networks (CCNs) decoded from the patient’s bulk tumor transcriptome. The model could (i) predict ICI efficacy for patients across four cancer types (median AUROC: 0.79) and (ii) identify key communication pathways with crucial players responsible for patient response or resistance to ICIs by analyzing more than 700 ICI-treated patient samples from 11 cohorts. The model prioritized chemotaxis communication of immune-related cells and growth factor communication of structural cells as the key biological processes underlying response and resistance to ICIs, respectively. We confirmed the key communication pathways and players at the single-cell level in patients with melanoma. Our network-based ML approach can be used to expand ICIs’ clinical benefits in cancer patients.

25 October 2022 in BMB Reports
Verified
Journal Article
Open access
PDF file
DHDoyeon Ha
Doyeon Ha
JKJungHo Kong
JungHo Kong
DKDonghyo Kim
Donghyo Kim
KLKwanghwan Lee
Kwanghwan Lee
JLJuhun Lee
Juhun Lee
SKSanguk Kim
Sanguk Kim
Doyeon Ha, JungHo Kong, Donghyo Kim, Kwanghwan Lee, Juhun Lee, Minhyuk Park, Hyunsoo Ahn, Youngchul Oh& Sanguk Kim. BMB Reports 2023;56:43-8. https://doi.org/10.5483/BMBRep.2022-0155

15 April 2022 in Molecules and Cells
Verified
Journal Article
Open access
PDF file
BCBongsoo Choi
Bongsoo Choi
DHDo Young Hyeon
Do Young Hyeon
JLJuhun Lee
Juhun Lee
TLTerri A. Long
Terri A. Long
DHDaehee Hwang
Daehee Hwang
Inhwang HwangInhwang Hwang
Inhwang Hwang
Bongsoo Choi, Do Young Hyeon, Juhun Lee, Terri A. Long, Daehee Hwang, and Inhwan Hwang. Mol. Cells 2022;45:294-305. https://doi.org/10.14348/molcells.2022.2029